|
Accession number;99A0233523
|
| Title;Prostate-Specific Antigen Values and Prognosis in Patients with Relapsed Prostate Cancer. |
| Author;
HORIGUCHI AKIO
(Otawara Red Cross Hosp.)
HATAKEYAMA NAOKI
(Otawara Red Cross Hosp.)
IKEUCHI KOICHI
(Otawara Red Cross Hosp.)
|
Journal Title;Nishinihon Journal of Urology
|
Journal Code:Z0253B
|
ISSN:0029-0726
|
|
VOL.61;NO.1;PAGE.16-21(1999)
|
| Figure&Table&Reference;FIG.7, TBL.2, REF.14 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;To identify prostate-specific antigen(PSA) functions of prognostic significance, we analyzed PSA parameters in 33 patients with relapsed prostate cancer following androgen deprivation. Pretreatment clinical stage was stage B in 1 patient, stage C in 6 patients, and stage D in 26 patients. All patients had biopsy-verified adenocarcinoma of the prostate, and were treated with endocrine therapy. Age and pretreatment PSA level did not significantly influence survival. Normalization of PSA level, high PSA decline rate, and early clinical stage were all associated with a prolonged progression-free period, but none of them significantly influenced survival period after relapse. The median progression-free period was 10.8 months. A prolonged progression-free period was not significantly correlated with a prolonged survival period after relapse. The PSA doubling time could be calculated in 27 patients. The median PSA doubling time was 46.6 days. There was a direct correlation between the PSA doubling time and the survival period after relapse, however the PSA doubling time was not correlated with any of the other PSA parameters. These data show that the PSA nadir and PSA doubling time following treatment provide important prognostic information. (author abst.) |
|
|
|
Related Articles;
|
